产品说明书

Favipiravir

Print
Chemical Structure| 259793-96-9 同义名 : 法维拉韦 ;T-705;Favilavir;Avigan
CAS号 : 259793-96-9
货号 : A265413
分子式 : C5H4FN3O2
纯度 : 99%
分子量 : 157.103
MDL号 : -
存储条件：

粉末 Inert atmosphere,2-8°C

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 105 mg/mL(668.35 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

H2O: 6 mg/mL(38.19 mM)，配合低频超声助溶
动物实验配方：
生物活性
靶点

  • RdRp
描述 Favipiravir (T 705) selectively inhibits the RNA-dependent RNA polymerase of influenza and other RNA viruses, demonstrating much higher selectivity for viral polymerase over human DNA polymerases and RNA polymerase II[1]. Favipiravir (T 705) functions as a pro-drug, with its cytotoxic effects varying by cell line. It dose-dependently inhibits MNV-induced cytopathic effects (CPE) with an EC50 of 250±11 μM and suppresses MNV RNA synthesis in cell culture with an EC50 of 124±42 μM. Although its antiviral efficacy is relatively modest, Favipiravir can fully stop norovirus replication at 100 μg/mL, a dosage that minimally impacts host cell viability (greater than 80%)[2].
细胞研究
细胞系 浓度 检测类型 检测时间 活动说明 数据源
MDCK cells Function assay Inhibition of viral replication of influenza A virus (A/Hong Kong/213/03(H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by neutral red uptake assay 17194832
MDCK cells Function assay Inhibition of influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) replication in MDCK cells by neutral red uptake assay 17194832
Vero cells Function assay 7-8 days Antiviral activity against Junin virus Candid-1 in Vero cells assessed as inhibition of virus-induced visual cytopathic effect after 7 to 8 days 17606691
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT01728753 Influenza Phase 1 Phase 2 Completed - United States, Florida ... 展开 >> Miami Research Associates Miami, Florida, United States, 33143 收起 <<
NCT02662855 Ebola Virus Disease Phase 2 Completed - -
NCT01068912 Influenza Phase 2 Completed - -
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

6.37mL

1.27mL

0.64mL

31.83mL

6.37mL

3.18mL

63.65mL

12.73mL

6.37mL
参考文献

[1]Furuta Y, et al. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res. 2013 Nov;100(2):446-54.

[2]Rocha-Pereira J, et al. Favipiravir (T-705) inhibits in vitro norovirus replication. Biochem Biophys Res Commun. 2012 Aug 10;424(4):777-80.

[3]Gao Y, et al. Cariprazine exerts antimanic properties and interferes with dopamine D2 receptor β-arrestin interactions. Pharmacol Res Perspect. 2015 Feb;3(1):e00073.